乳腺癌分子亚型不能预测放疗分次敏感性:大样本前瞻队列分析
该研究基于2005-2009年诊断的5868例I-III期乳腺癌患者,中位随访10.8年,比较了不同分子亚型(Luminal-A、Luminal-B、HER2+、三阴性)接受大分割放疗与常规分次放疗的10年局部无复发生存(LRFS)。结果显示各亚型间大分割与常规分次放疗的10年LRFS均无显著差异,且亚型与分次方案无显著交互作用,支持在所有乳腺癌亚型中常规使用大分割放疗。
要点
- 10年LRFS全队列97.1%,三阴性最低93.5%,Luminal-A最高98.3%。
- 各分子亚型中大分割与常规分次的10年LRFS均无显著差异。
- 亚型与分次方案无显著交互作用,支持各亚型常规使用大分割。
核心结论
- 数据支持在所有乳腺癌分子亚型中常规使用大分割放疗方案。
研究设计与样本
- 研究为前瞻性收集队列,纳入2005-2009年诊断的I-III期乳腺癌患者共5868例,中位随访10.8年。
- 分子亚型按AJCC分类系统分为Luminal-A、Luminal-B、HER2+和三阴性(TN)。
- 采用多变量Cox回归建模识别LR预测因素,Kaplan-Meier法计算LRFS并用log-rank检验比较。
主要发现
- 全队列10年LRFS为97.1%(95%CI 96.6-97.6)。
- 亚型与分次方案之间无显著交互作用。
临床怎么用
- 对于I-III期乳腺癌患者,无论分子亚型如何,均可考虑常规采用大分割放疗方案。
- 三阴性亚型10年LRFS相对较低(93.5%),但大分割与常规分次疗效无显著差异,仍可安全使用大分割。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The predictive benefit of breast cancer molecular subtypes for systemic therapy approaches has been well established; yet, there is a paucity of data regarding their use as a predictor of radiation therapy fractionation sensitivity. The purpose of this study was to determine whether rates of local recurrence (LR) for patients treated with hypofractionated (HF) radiation therapy, in comparison to conventional fractionation, differ across breast cancer molecular subtypes in a large, prospectively collected cohort treated with modern systemic therapy. METHODS AND MATERIALS: Patients who received a diagnosis of stage I-III breast cancer between 2005 and 2009 were identified. Molecular subtype was determined using the American Joint Committee on Cancer classification system (luminal-A, luminal-B, HER2+, triple negative [TN]). Multivariable Cox regression modeling was used to identify predictors of LR. LR-free-survival (LRFS) was determined using the Kaplan-Meier method and compared using the log-rank test. RESULTS: A total of 5868 cases were identified with a median follow-up of 10.8 years. Patients with luminal-A subtype composed 45% of the cohort (n = 2628), compared with 30% luminal-B (n = 1734), 15% HER2+ (n = 903), and 10% TN (n = 603). A total of 76% (n = 4429) of patients were treated with HF. The 10-year LRFS was 97.1% (95% confidence interval [CI], 96.6-97.6) for the whole cohort. The 10-year LRFS based on molecular subtypes was 98.3% (95% CI, 97.6-98.7) luminal-A, 96.6% (95% CI, 95.5-97.4) luminal-B, 97.0% (95% CI, 95.5-98.0) HER2+, and 93.5% (95% CI, 91.1-95.3) TN (P < .001). There was no difference in the 10-year LRFS between patients treated with HF versus conventional fractionation among those with luminal-A (98.2% vs 98.4%; P = .42), luminal-B (96.6% vs 96.8%; P = .90), HER2+ (97.5% vs 95.8%; P = .12), or TN (93.9% vs 92.2%; P = .47). There was no significant interaction between subtype and fractionation regimen. CONCLUSIONS: These data support the routine use of hypofractionated radiation therapy regimens across all breast cancer subtypes.
引用
- Lalani N, Voduc KD, Jimenez RB, et al. Breast Cancer Molecular Subtype as a Predictor of Radiation Therapy Fractionation Sensitivity. Int J Radiat Oncol Biol Phys. 2020. PMID: 32853707. doi:10.1016/j.ijrobp.2020.08.038
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。